IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1747 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission

 


This article has been cited by
1Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
Nayoung Han,Jung Mi Oh,In-Wha Kim
Scientific Reports.2020;10(1)
[DOI]
2Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
Maria Sole Vallecoccia,Orla Anne Murphy,Alejandro H. Rodriguez,Ignacio Martin-Loeches
Scientific Reports.2022;10(1)350
[DOI]
3Exploring the chemical space of influenza neuraminidase inhibitors
Nuttapat Anuwongcharoen,Watshara Shoombuatong,Tanawut Tantimongcolwat,Virapong Prachayasittikul,Chanin Nantasenamat
PeerJ.2016;4(1)e1958
[DOI]
4Opportunities for the development of novel therapies based on host-microbial interactions
Patrícia Campi Santos,Mauro Martins Teixeira,Danielle G. Souza
Pharmacological Research.2016;112(1)68
[DOI]
5Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009–15
C. Boikos,C. Caya,M. K. Doll,H. Kraicer-Melamed,M. Dolph,G. Delisle,N. Winters,G. Gore,C. Quach
Journal of Antimicrobial Chemotherapy.2017;72(6)1556
[DOI]
6Oseltamivir and baloxavir: Dual treatment for rapidly developing ARDS on a patient with renal disease
Pool Tobar Vega,Elena Caldeira,Hasan Abad,Peguy Saad,Erik Lachance
IDCases.2020;21(6)e00819
[DOI]
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow